
Overview
Status
Active
Registry date
2023-10-13
Registered address
ul. Droga Leśna 59/12, 64-600 Oborniki, Poland
Website
mimobiotech.comWebsite active
Email
Email address current
Financials
Revenue history
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Maciej Drożdż – President of the Management Board
Manner of representation
If the management board consists of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner |
|---|
Maciej Drożdż (53) |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| GenxoneS.A. | $665,361.35 | genxone.eu | ||
| Polbiotech Laboratoriumsp. z o.o. | $645,943.81 | polbiotech.pl | ||
| Relvosp. z o.o. | $120,693.26 | relvo.pl | ||
| Microblicsp. z o.o. | $122,383.50 | microblic.pl | ||
| AI Corelabsp. z o.o. | $106,857.00 | aicorelab.com | ||
| Xenstatssp. z o.o. | $66,774.27 | xenstats.com | ||
| Data2biologysp. z o.o. | $28,567.58 | data2biology.com | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Fungotechsp. z o.o. | $187.68 | fungo.tech |
FAQ
The main business activity of Mimo Biotech focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on October 13, 2023.
The headquarters is located at: ul. Droga Leśna 59, 64-600 Oborniki.
The management board consists of: Maciej Drożdż (President of the Management Board).
The share capital of the company is PLN 1 (approx. $0).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
No, the company recorded a net loss of USD 4,211 in 2025. For comparison, in 2024 the loss was USD 4,394, meaning the company reduced its loss by 4.4%.
The largest operating cost category falls under other operating costs. This category amounted to USD 4,211 in 2025, representing 100% of all operating expenses.
Last updated: 2026-10-07